Saturday, July 12, 2025

Latest

MediPharm Labs Posts Revenues Of $5.5 Million, Net Loss Of $13.9 Million

MediPharm Labs (TSX: LABS) this morning continued its recent trend of dismal financing results, posting revenues of just $5.5 million for the period ended March 31, 2021, along with a net loss of $13.9 million for the three month period.

Revenues were down 9.9% on a quarter over quarter basis from the $6.1 million in revenues the company posted for the fourth quarter of 2020. The company blamed the decline of “challenging operating conditions” within the domestic Canadian retail cannabis market, and reduced purchasing from provincial regulators. Recreational sales declined 40% quarter over quarter to $3.4 million, while international sales grew to $2.1 million.

Things didn’t get better from here, with cost of sales coming in at $6.2 million, resulting in a negative gross profit of $0.7 million. Operating expenses continued this trend, with the company posting an operating loss of $7.9 million. The largest expenses here consisted of G&A expenditures of $4.0 million, as well as marketing and selling expenses of $1.3 million.

After a final finance expense of $9.7 million which was partially offset by an unrealized gain in derivates to the tune of $3.7 million, the company posted an overall net loss of $13.9 million.

The company has yet to name a new CEO following the stepping down of Pat McCutcheon late last year, with the company simply stating that several candidates have been identified.

MediPharm Labs last traded at $0.40 on the TSX.


.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Medipharm Labs Sells Off Australian Assets

MediPharm Labs (TSX: LABS) appears to be slowly pulling back on its international endeavours. The...

Monday, July 11, 2022, 08:11:52 AM

Cronos Group Subject Of SEC Inquiry

This evening, MarketWatch reporter Max Cherney broke the story that Cronos Group (TSX: CRON) (NASDAQ:...

Thursday, March 19, 2020, 09:59:02 PM

Medipharm Labs Reports Q4 Revenues Of $6.1 Million, Net Loss Of $30.9 Million

Medipharm Labs (TSX: LABS) this morning reported its fourth quarter financial results for 2020. Revenues...

Wednesday, March 31, 2021, 07:47:27 AM

Medipharm Labs Closes $33.4 Million Bought Deal Financing

Medipharm Labs (TSX: LABS) has closed the bought deal financing that it announced and then...

Friday, March 5, 2021, 09:12:09 AM

MediPharm Labs: Canaccord Resumes Coverage, Issues $2.25 Price Target

As a follow up to the earlier covered resumption of coverage by Canaccord Genuity on...

Monday, July 6, 2020, 04:53:00 PM